Investigational drug apabetalone, a BET protein inhibitor, was not effective compared with placebo in lowering adverse cardiovascular outcomes in patients with type 2 diabetes and acute coronary syndrome at 26 months. The study, presented at the American Heart Association meeting, used data from 2,418 patients and found that 10.3% of those taking apabetalone experienced CV death, non-fatal myocardial infarction or stroke, compared with the 12.4% of patients who were taking placebo.
Apabetalone does not lower CV risk in patients with T2D, ACS
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.